 |
dexanabinol |
|---|---|
| Trade Name | |
| Orphan Indication | For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury |
| USA Market Approval | USA |
| USA Designation Date | 2004-08-11 00:00:00 |
| Sponsor | Pharmos Corporation;99 Wood Avenue, Suite 311;Iselin, New Jersey, 08830 |
